Polycystic Kidney Disease

• Primary ciliary dysfunction and mechanotransduction abnormalities: The pathophysiologic foundation of ADPKD involves mutations in PKD1 (chromosome 16p13.3, encoding polycystin-1) in ~85% of cases or PKD2 (chromosome 4q21, encoding polycystin-2) in ~15% of cases. Polycystin-1 is a large 4,302-amino acid transmembrane receptor localized to primary cilia and the plasma membrane, while polycystin-2 (also termed TRPP2) is a transient receptor potential cation channel also localized to cilia. The primary cilium is an organelle projecting from the apical surface of renal tubular epithelial cells that functions as a cellular "antenna" detecting fluid flow and mechanical stimuli through polycystin-1/polycystin-2 heteromeric complexes. Under normal conditions, tubular fluid flow activates the polycystin complex, triggering calcium influx through polycystin-2 and suppressing cAMP-dependent signaling pathways. Loss of functional polycystin-1 or polycystin-2 eliminates this mechanotransductive response, resulting in unopposed elevation of intracellular cAMP levels in tubular epithelial cells. This persistent cAMP elevation activates protein kinase A (PKA), which phosphorylates the cystic fibrosis transmembrane conductance regulator (CFTR) and other targets, promoting aberrant chloride and fluid secretion into the tubular lumen—the primary mechanism driving cyst expansion. The "two-hit hypothesis" suggests that while inherited mutations provide a germline defect, somatic inactivation of the normal allele (loss of heterozygosity) in individual tubular cells accelerates cyst formation through complete loss of functional protein, explaining the multifocal and progressive nature of cyst development.

• Abnormal cell proliferation and epithelial-mesenchymal transition (EMT): Beyond cAMP dysregulation, PKD cells exhibit intrinsically elevated proliferation rates driven by multiple intersecting pathways. Enhanced phosphatidylinositol 3-kinase (PI3K)/AKT signaling promotes cell survival, while altered Wnt/β-catenin and Notch signaling pathways drive tubular epithelial cell proliferation beyond homeostatic levels. Tubular epithelial cells in cystic tissue undergo partial epithelial-mesenchymal transition (EMT), acquiring mesenchymal markers (vimentin, α-smooth muscle actin) and losing epithelial characteristics (E-cadherin downregulation), contributing to dedifferentiation, increased motility, and enhanced proliferation. This EMT process is mediated by upregulation of transcription factors including Snail, Slug, and Twist, often triggered by dysregulated growth factor signaling (hepatocyte growth factor [HGF], fibroblast growth factor [FGF], epidermal growth factor [EGF]) consequent to impaired ciliary signaling. Additionally, inflammatory cytokine production (IL-6, TNF-α) from cyst-lining cells and infiltrating immune cells perpetuates proliferation and contributes to the fibrotic microenvironment.

• Progressive interstitial fibrosis and CKD development: While cyst expansion accounts for the dramatic radiographic appearance of PKD, progressive loss of renal function is primarily driven by interstitial fibrosis and tubular atrophy in non-cystic kidney regions. Hypoxia in the expanding PKD kidney—stemming from increased diffusion distances from cysts and altered microvascular architecture—stabilizes hypoxia-inducible factor 1α (HIF-1α), promoting fibroblast activation and collagen deposition. The dysregulated cAMP-PKA pathway in cyst-lining cells promotes the secretion of profibrotic cytokines including TGF-β, which paracrinically activates peritubular fibroblasts to differentiate into myofibroblasts and produce excessive extracellular matrix. Chronic activation of the renin-angiotensin-aldosterone system (RAAS)—both systemically and within the kidney—further amplifies TGF-β signaling and fibroblast activation. Renal hemodynamic changes, including glomerular hyperfiltration in the remaining functional nephrons, perpetuate proteinuria and progressive glomerulosclerosis. The accumulation of these pathologic processes results in progressive nephron loss and declining glomerular filtration rate (GFR), with the tempo of decline varying based on PKD1 versus PKD2 mutations, sex, blood pressure control, and proteinuria burden.

• Cyst fluid secretion and osmotic cyst expansion: Cyst growth is sustained by active fluid secretion into the cystic lumen driven by dysregulated electrolyte transport. The cAMP-mediated phosphorylation and activation of CFTR at the apical membrane of cyst-lining cells allows chloride secretion into the cystic fluid, followed by sodium and water reabsorption to maintain electroneutrality and osmotic balance. Aquaporin-1 and aquaporin-3 water channels facilitate water transport across the cyst epithelium, enabling osmotic-driven cyst expansion. Additionally, vasopressin (antidiuretic hormone [ADH]) is a potent activator of cAMP synthesis via V2 receptor signaling in collecting duct cells, and elevated vasopressin levels in PKD patients (secondary to volume depletion from progression to CKD) further drive cAMP accumulation and cyst expansion. This mechanistic linkage between vasopressin and cyst growth forms the rationale for vasopressin V2 receptor antagonist therapy.

• ARPKD-specific pathophysiology: ARPKD results from mutations in the PKHD1 gene (chromosome 6p12.2), encoding fibrocystin, a large transmembrane protein localized to primary cilia and centrosomes. Fibrocystin mutations impair ciliary-mediated signaling and centrosome function, resulting in disrupted tubulogenesis, progressive cystic dilation of collecting ducts in utero, and congenital hepatic fibrosis. ARPKD typically manifests in the perinatal period or early infancy with severe bilateral renal enlargement, oligohydramnios, pulmonary hypoplasia, and oliguria or anuria, contrasting sharply with the adult-onset progressive disease pattern of ADPKD.

• Autosomal dominant PKD (ADPKD): Accounts for ~85% of inherited PKD cases and ~8–10% of ESRD globally. PKD1 mutations (85% of ADPKD; chromosome 16p13.3) confer a more aggressive disease phenotype with median renal survival to ESRD at approximately 50 years of age and higher cardiovascular morbidity. PKD2 mutations (15% of ADPKD; chromosome 4q21) result in slower disease progression with median renal survival to ESRD extending to approximately 79 years of age. De novo mutations account for approximately 10% of ADPKD cases in patients without a family history, necessitating genetic testing when suspicion is high. The penetrance of ADPKD approaches 100% by the eighth decade of life, meaning that genetic carriers will invariably manifest the disease phenotype.

• Autosomal recessive PKD (ARPKD): A much rarer form with an incidence of approximately 1 in 20,000 live births, caused by homozygous or compound heterozygous mutations in PKHD1 (fibrocystin gene; chromosome 6p12.2). ARPKD presents with markedly different natural history compared to ADPKD, manifesting prenatally or in infancy with severe bilateral renal enlargement, collecting duct cystic dilation, and congenital hepatic fibrosis. Perinatal ARPKD (85% of cases) presents with severe pulmonary hypoplasia and oligohydramnios due to severe bilateral renal enlargement impairing amniotic fluid production via decreased fetal urine output. Infancy-onset ARPKD (15% of cases) may have milder renal involvement but significant hepatic fibrosis and portal hypertension. Disease progression in ARPKD leads to ESRD in childhood or adolescence but varies by mutation severity.

• Genetic modifier factors and PKD1 complications: Specific PKD1 mutations correlate with phenotypic severity—truncating mutations (nonsense, frameshift) generally confer more rapid progression than missense mutations. Male sex, African American ethnicity, and PKD1 genotype (versus PKD2) are associated with accelerated renal disease progression and earlier ESRD onset. Hypertension, proteinuria burden, and declining baseline GFR at diagnosis are modifiable risk factors predicting more rapid nephron loss. Intracranial aneurysm (ICA) prevalence correlates with PKD1 mutations, particularly with large deletions or truncating mutations affecting the N-terminal region.

• Secondary acquired "cystic kidney disease": While not a primary inherited disorder, acquired renal cystic disease (CKD-associated simple cysts) can occur in patients with chronic kidney disease from various etiologies and should be distinguished from inherited PKD by clinical context (late onset, CKD history, imaging pattern of simple cysts rather than numerous bilateral cysts).

• Hypertension and its complications: Hypertension is the most common clinical manifestation of ADPKD, present in approximately 50–60% of patients before significant renal function decline (CKD stage 3 or worse). The pathogenesis involves both RAAS activation from cyst compression of renal vasculature and interstitial fibrosis causing local angiotensin II and aldosterone production, as well as impaired renal sodium handling and volume expansion. Hypertension in PKD often manifests insidiously and may precede detectable renal function decline, making it the presenting sign in many patients. Poorly controlled hypertension accelerates the decline in GFR and increases the risk of cardiovascular events, stroke, and left ventricular hypertrophy (LVH). Some patients present with hypertensive emergencies including hypertensive encephalopathy, though this is less common in the contemporary era with improved pharmacologic management.

• Flank or abdominal pain: Presents in approximately 50% of symptomatic ADPKD patients, typically described as dull, chronic flank or lower back pain reflecting kidney enlargement and stretching of the renal capsule. Pain may be acute and severe when cyst rupture or hemorrhage occurs (see complications section). The pain is often bilateral and may be worse with physical exertion or prolonged standing. Some patients develop chronic pain syndromes, and analgesic use is often complicated by the need to avoid NSAIDs given their nephrotoxic potential and the progressive decline in renal function. Rarely, severe chronic pain may warrant nephrectomy despite preserved renal function in selected cases.

• Hematuria: Gross hematuria occurs in approximately 35% of ADPKD patients and may be the presenting manifestation, particularly following minor trauma or Valsalva maneuver. Hematuria typically results from rupture of small cyst vessels into the tubular system, is usually self-limited, and resolves spontaneously within several days. Microscopic hematuria is nearly universal in ADPKD patients. It is important to distinguish PKD-related hematuria from other causes such as stone disease, infection, or glomerular bleeding (as evidenced by dysmorphic RBCs or RBC casts). Persistent or symptomatic hematuria warrants investigation to exclude comorbid conditions.

• Urinary tract infections (UTIs) and pyelonephritis: Recurrent UTIs occur in 20–30% of ADPKD patients and pyelonephritis in 15–30%, more common in women, reflecting cyst complications (cyst infection), impaired immune defenses in cystic fluid, and urinary stasis. UTI-related sepsis can progress rapidly in PKD patients given the large renomegaly and diminished renal clearance capacity. Patients frequently develop recurrent episodes and may require prophylactic antibiotics; however, cyst infections themselves may not reliably yield positive urine cultures as infected cysts may not communicate directly with the urinary system. Fever, flank pain, and elevated inflammatory markers (leukocytosis, elevated CRP/ESR) in a PKD patient should prompt investigation for both UTI and occult cyst infection.

• Progressive renal dysfunction and chronic kidney disease symptoms: Advancing CKD develops insidiously as cyst burden increases and interstitial fibrosis expands. Patients with CKD stage 4–5 develop characteristic uremia symptoms including fatigue, anorexia, nausea, altered taste sensation, and cognitive difficulties. Polyuria and nocturia may paradoxically persist in early-to-mid disease despite declining GFR, reflecting cyst fluid secretion overwhelming the tubule's reabsorptive capacity (in contrast to non-PKD CKD where oliguria is typical). Anemia develops secondary to EPO deficiency and chronic inflammation, contributing to fatigue. The progression to ESRD requiring renal replacement therapy typically occurs by age 50 in PKD1 patients and age 79 in PKD2 patients, though individual variation is substantial.

• Extrarenal manifestations—Hepatic cysts: Hepatic cyst involvement occurs in 75–90% of ADPKD patients, though rarely causes clinical symptoms or significant hepatic dysfunction even when extensive. The cysts are typically asymptomatic and non-progressive in most patients. Rarely, massive hepatomegaly from very large cystic burden may cause abdominal distension or discomfort. ARPKD patients characteristically develop congenital hepatic fibrosis with portal hypertension and risk of complications including variceal bleeding and hepatic encephalopathy.

• Extrarenal manifestations—Cardiovascular: Cardiac valve abnormalities are present in 25% of ADPKD patients, most commonly mitral valve prolapse (MVP), followed by aortic regurgitation and tricuspid regurgitation. These valvular abnormalities are generally hemodynamically insignificant but increase the risk of infective endocarditis; antibiotic prophylaxis for certain procedures is recommended. Left ventricular hypertrophy (LVH) is present in 40–50% of ADPKD patients, driven primarily by chronic hypertension and is associated with increased cardiovascular morbidity and mortality. Coronary artery disease risk is elevated in ADPKD due to the combined effects of hypertension, proteinuria, and dyslipidemia. Some patients have diastolic dysfunction or dilated cardiomyopathy from combined effects of LVH and hypertension.

• Intracranial aneurysms (ICA): Occur in 8–10% of the general ADPKD population (versus 0.5–1% in non-PKD), and prevalence reaches 20–23% in patients with a family history of ICA or subarachnoid hemorrhage. PKD1 mutations carry higher ICA risk than PKD2. Aneurysms are typically located in the anterior circulation (anterior communicating artery, middle cerebral artery bifurcation). Asymptomatic aneurysms are managed with noninvasive surveillance (MR angiography [MRA] or CT angiography [CTA]) every 5 years; symptomatic aneurysms or those enlarging on serial imaging warrant endovascular coiling or surgical clipping. Ruptured aneurysm presents as acute severe headache, neck stiffness, and meningeal signs (classic subarachnoid hemorrhage presentation) and is a medical emergency requiring immediate

Initial test — renal ultrasound

• Ultrasound is first-line in an at-risk patient (affected first-degree relative): inexpensive, no radiation, no contrast. Findings are bilaterally enlarged kidneys with innumerable anechoic cysts replacing normal parenchyma.
• Unified (Pei–Ravine) ultrasound criteria stratify cyst counts by age because simple cysts accumulate with aging: ages 15–39, ≥3 cysts total (unilateral or bilateral); ages 40–59, ≥2 cysts in each kidney; age ≥60, ≥4 cysts in each kidney. Fewer than 2 cysts total in an at-risk person ≥40 essentially excludes ADPKD — the exclusion rule that matters when screening a potential living kidney donor.

Confirmatory and prognostic imaging

• Contrast-free MRI (or CT): more sensitive than ultrasound for small cysts and the reference standard for total kidney volume (TKV). Height-adjusted TKV plus age generates the Mayo Imaging Classification (typical diffuse disease, classes 1A–1E), which identifies rapid progressors and drives drug eligibility.
• Genetic testing (PKD1/PKD2, PKHD1): reserved for equivocal imaging, very early or atypical presentations, absent family history (de novo mutation), donor evaluation, and reproductive counseling — not needed when imaging is classic.

Supporting labs and syndrome-specific work-up

• Baseline renal assessment: serum creatinine/eGFR, urinalysis (microscopic hematuria, bland sediment, low-grade proteinuria), urine albumin-to-creatinine ratio, and electrolytes. Impaired urinary concentrating ability appears early.
• Intracranial aneurysm screening: per KDIGO ADPKD consensus, MR angiography is targeted, not universal — offered for a family history of aneurysm or subarachnoid hemorrhage, prior rupture, or high-risk occupation.
• ARPKD: prenatal or neonatal ultrasound shows massively enlarged, diffusely echogenic kidneys with loss of corticomedullary differentiation, oligohydramnios, and hepatic findings of congenital hepatic fibrosis; parents are unaffected.

Foundation — blood pressure and RAAS blockade

• ACE inhibitor or ARB (e.g., lisinopril) is first-line antihypertensive therapy, targeting the intrarenal RAAS activation produced by cyst compression; the HALT-PKD trials supported rigorous BP control in younger patients with preserved eGFR. KDIGO's blood pressure and CKD guidance favors intensive systolic targets using standardized measurement.
• Avoid dual RAAS blockade (ACEI + ARB): no added benefit, more hyperkalemia and AKI.
• ACE inhibitors and ARBs are contraindicated in pregnancy (fetal renal dysgenesis, oligohydramnios) — this includes captopril; switch women planning pregnancy to labetalol or nifedipine per ACOG.

Disease-modifying therapy

• Vasopressin V2 receptor antagonist — tolvaptan: the only FDA-approved agent to slow eGFR decline in adults at risk of rapidly progressive ADPKD (TEMPO 3:4, REPRISE). It blocks V2-mediated cAMP generation, the same pathway driving CFTR-mediated cyst fluid secretion.
• Requires a REMS program with serial ALT and bilirubin (frequent monitoring early, then periodically) because of idiosyncratic hepatotoxicity; contraindicated with significant liver disease, uncorrected sodium abnormalities, or inability to sense/respond to thirst.
• Expect aquaresis: polyuria, nocturia, thirst, hypernatremia.
• Supportive measures: generous water intake to suppress endogenous vasopressin, dietary sodium restriction, weight control, smoking cessation, and avoidance of chronic NSAIDs and nephrotoxins.

Complication-directed and definitive care

• Pain: acetaminophen first; cyst aspiration/sclerotherapy or laparoscopic cyst decortication for dominant symptomatic cysts; nephrectomy only for intractable pain or recurrent hemorrhage/infection.
• Cyst infection: lipophilic, cyst-penetrating antibiotics — fluoroquinolone (ciprofloxacin) or trimethoprim–sulfamethoxazole — for a prolonged course; drain if refractory. Beta-lactams penetrate cysts poorly.
• ESRD: dialysis or, preferably, kidney transplantation (definitive); native nephrectomy only when needed for space, bleeding, or chronic infection.

Renal complications

• Cyst hemorrhage: rupture of stretched perycystic vessels after exertion or minor trauma → acute unilateral flank pain with gross hematuria, usually self-limited with rest, hydration, and analgesia. Retroperitoneal hemorrhage with hemodynamic instability is an emergency requiring imaging and possible angioembolization.
• Cyst infection: signals itself as fever plus focal, localized flank tenderness with elevated CRP; urine culture is often negative because the cyst may not communicate with the collecting system. Refractory sepsis is an emergency; FDG-PET/CT can localize the infected cyst when CT/MRI is inconclusive.
• Nephrolithiasis (~20% of patients): urinary stasis, low urine citrate, and low urine pH favor uric acid and calcium oxalate stones — an important distractor since ADPKD stones are frequently radiolucent.
• Progressive CKD/ESRD: driven by interstitial fibrosis, not cyst number alone.

Extrarenal complications

• Ruptured intracranial aneurysm: worst headache of life, meningismus, sudden neurologic deficit — a true emergency. Non-contrast head CT first; lumbar puncture for xanthochromia if CT is negative and suspicion persists.
• Polycystic liver disease: mass effect, rarely infection; estrogen exposure accelerates hepatic cyst growth. In ARPKD, congenital hepatic fibrosis produces portal hypertension with variceal bleeding — a bleeding varix is an emergency.
• Colonic diverticulosis, abdominal wall and inguinal hernias, mitral valve prolapse, thoracic aortic and coronary aneurysms: connective-tissue/ciliopathy phenotype.

Treatment-related complications

• Tolvaptan: idiosyncratic hepatotoxicity (rising ALT with bilirubin — Hy's law pattern; stop the drug) and aquaresis-driven hypernatremia/volume depletion if thirst is not accessible.
• ACEI/ARB: hyperkalemia and functional eGFR decline, exaggerated with volume depletion or NSAIDs; fetotoxic in pregnancy.
• Post-transplant immunosuppression: infection and malignancy risk; acquired cystic disease of dialysis (not ADPKD itself) is the setting classically linked to renal cell carcinoma.

• Buzzword pairing: a young–middle-aged adult with hypertension + bilateral flank masses + hematuria + a positive family history is ADPKD until proven otherwise; the single best next step is renal ultrasound, not CT and not genetic testing.
• Genotype drives timing: PKD1 (chromosome 16, polycystin-1) is more common and reaches ESRD roughly two to three decades earlier than PKD2 (chromosome 4, polycystin-2). Sixteen letters in "polycystic kidney" is a common mnemonic for PKD1/chromosome 16.
• The association examiners test: berry (saccular) aneurysm of the anterior circulation → subarachnoid hemorrhage. Screening MRA is selective (family history of aneurysm/SAH, prior rupture, high-risk occupation), not universal. Thunderclap headache → non-contrast head CT first.
• Tolvaptan is the drug to know: V2 receptor antagonist that lowers cAMP and slows eGFR decline in rapid progressors; its two board-tested toxicities are hepatotoxicity (REMS liver monitoring) and aquaresis with hypernatremia.
• Fever + localized flank pain + negative urine culture = infected cyst. Choose a lipophilic, cyst-penetrating antibiotic (fluoroquinolone or TMP-SMX); beta-lactams are the trap answer because they penetrate cysts poorly.
• ADPKD vs ARPKD: ADPKD has hepatic cysts; ARPKD has congenital hepatic fibrosis with portal hypertension. The neonate with Potter sequence — oligohydramnios, pulmonary hypoplasia, limb deformities, bilateral echogenic kidneys — is ARPKD (PKHD1, fibrocystin).
• Distractors to avoid: renal cell carcinoma is classically linked to acquired cystic kidney disease of dialysis and to von Hippel–Lindau, not to ADPKD per se; and ADPKD stones are typically uric acid (radiolucent), not uniformly calcium.
• Pregnancy pitfall: ACE inhibitors and ARBs are contraindicated — captopril's short half-life makes it useful for rapid titration outside pregnancy, never within it.